e-Therapeutics plc Further re: Directors' Shareholdings (5273L)

TIDMETX

RNS Number : 5273L

e-Therapeutics plc

03 October 2016

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Further re: Directors' Shareholdings

3 October 2016, Oxford and Newcastle, UK: Further to e-Therapeutics' announcement on 21 September 2016, the Company announces the following additional detail on the increase to Sean Nicolson's shareholding in the Company; this information is made in accordance with the requirements of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
----  ------------------------------------------------------------ 
 a)    Name                       Sean Nicolson 
----  -------------------------  --------------------------------- 
 2     Reason for the notification 
----  ------------------------------------------------------------ 
 a)    Position/status            Director 
----  -------------------------  --------------------------------- 
 b)    Initial                    Amendment 
        notification 
        /Amendment 
----  -------------------------  --------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
----  ------------------------------------------------------------ 
 a)    Name                       e-Therapeutics plc 
----  -------------------------  --------------------------------- 
 b)    Legal Entity               N/A 
        Identifier 
----  -------------------------  --------------------------------- 
 4     Details of the transaction(s): section 
        to be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
----  ------------------------------------------------------------ 
 a)    Description                 Ordinary shares of 0.1 pence 
        of the financial            each 
        instrument, 
        type of instrument 
 
        Identification              GB00B2823H99 
        code 
----  --------------------------  -------------------------------- 
 b)    Nature of                   Award of shares 
        the transaction 
----  --------------------------  -------------------------------- 
 c)    Currency                    GBP 
----  --------------------------  -------------------------------- 
 d)    Price(s) and                Price(s)            Volume(s) 
        volume(s) 
----  --------------------------  ------------------  ------------ 
    14.55 pence                                        2,166 
   -------------------------------------------------  ------------ 
 
 e)    Aggregated 
        information 
   - Aggregated 
    volume 
   - Price                     2,166 
   - Aggregated                 14.55 pence per share 
    total 
                                GBP315.15 
 --------------------------  ------------------------------------- 
 f)    Date of the                 21 September 2016 
        transaction 
----  --------------------------  -------------------------------- 
 g)    Place of the                London Stock Exchange (AIM) 
        transaction 
----  --------------------------  -------------------------------- 
 
 

Contacts:

 
 e-Therapeutics plc                   Tel: [phone] 
  Iain Ross, Chairman                  883 125 
  Steve Medlicott, Finance Director    www.etherapeutics.co.uk 
 Numis Securities Limited             Tel: [phone] 
  Michael Meade / Freddie Barnfield    1000 
  (Corporate Finance)                  www.numis.com 
  James Black (Corporate Broking) 
 Instinctif Partners                  Tel: [phone] 
  Melanie Toyne-Sewell / Jayne         2020 
  Crook / Emma Barlow                  Email: [e-mail] 
 

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.

e-Therapeutics has a variety of preclinical stage assets, including ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFIVIFLVIIR

(END) Dow Jones Newswires

October 03, 2016 09:03 ET (13:03 GMT)